Dana-Farber Cancer Institute, Inc Patent Portfolio Statistics

Dana-Farber Cancer Institute, Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Dana-Farber Cancer Institute, Inc. look like?

Total Applications: 1,160
Granted Patents: 596
Grant Index 71.81 %
Abandoned/Rejected Applications: 234 (28.19%)
In-Process Applications: 325
Average Grant Time: 3.28 Years
Average Office Actions: 2.22

Which Technology Area Dana-Farber Cancer Institute, Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1642 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 128
1624 Organic Chemistry 74
1634 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 71
1644 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 61
Opap Parked GAU 60

How many patents are Dana-Farber Cancer Institute, Inc. filing every year?

Year Total Applications
2022 0*
2021 30*
2020 109
2019 104
2018 112

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Dana-Farber Cancer Institute, Inc. in USPTO?

Publication number:
Application number: 17/534,896

Abstract:
None

Publication date:
Applicant: Dana-Farber Cancer Institute, Inc.
Inventors: Buhrlage Jean Sara


Publication number: US20220023233A1
Application number: 17/494,830

Abstract:
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.

Publication date: 2022-01-27
Applicant: Dana-Farber Cancer Institute, Inc.
Inventors: Alimova Maria


Publication number: US20220017510A1
Application number: 17/449,027

Abstract:
The present application provides bifunctional compounds of Formula (I):which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.

Publication date: 2022-01-20
Applicant: Dana-Farber Cancer Institute, Inc.
Inventors: Jaebong Jang


How are Dana-Farber Cancer Institute, Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/534,896 Methods To Treat Lymphoplasmacytic Lymphoma Application Undergoing Preexam Processing 1624
17/494,830 Agents For Reversing Toxic Proteinopathies OPAP Central, Docket
17/449,027 Bifunctional Molecules For Degradation Of Egfr And Methods Of Use OPAP Central, Docket
17/431,835 Treatment Of Liver Injury
17/399,563 C-Raf Mutants That Confer Resistance To Raf Inhibitors Docketed New Case – Ready for Examination OPAP Central, Docket